AMD 3465 (hexahydrobromide)

AMD 3465 (hexahydrobromide)

• CAS Number: 185991-07-5
• UNSPSC Description: AMD 3465 hexahydrobromide (GENZ-644494 hexahydrobromide) is a potent antagonist of CXCR4, inhibits binding of 12G5 mAb and CXCL12AF647 to CXCR4, with IC50s of 0.75 nM and 18 nM in SupT1 cells; AMD 3465 also potently inhibits the replication of X4 HIV strains (IC50: 1-10 nM), but has no effect on CCR5-using (R5) viruses.
• Target Antigen: CXCR; HIV
• Type: Reference compound
• Related Pathways: Anti-infection;GPCR/G Protein;Immunology/Inflammation
• Applications: COVID-19-anti-virus
• Field of Research: Infection; Endocrinology
• Assay Protocol: https://www.medchemexpress.com/AMD-3465-hexahydrobromide.html
• Solubility: DMSO : 50 mg/mL (ultrasonic)|H2O : ≥ 38 mg/mL
• Smiles: [H]Br.[H]Br.[H]Br.[H]Br.[H]Br.[H]Br.C1(CNCC2=CC=C(CN3CCNCCCNCCNCCC3)C=C2)=NC=CC=C1
• Molecular Weight: 896.07
• References & Citations: [1]Hatse S, et al. AMD3465, a monomacrocyclic CXCR4 antagonist and potent HIV entry inhibitor. Biochem Pharmacol. 2005 Sep 1;70(5):752-61.|[2]Yang L, et al. Blocking CXCR4-mediated cyclic AMP suppression inhibits brain tumor growth in vivo. Cancer Res. 2007 Jan 15;67(2):651-8.Biomed Pharmacother. 2021 Mar 24;138:111476.|J Labelled Comp Radiopharm. 2018 May 15;61(5):438-446. |Patent. US20180263995A1.|Br J Haematol. 2022 Dec 19.
• Shipping Conditions: Room Temperature
• Clinical Information: No Development Reported